Dermatology · 2005 · 30 citations · 7 references
MedicineDermatologyPharmacotherapyDermatopathologyImmunopathologyTransplant ImmunologyCalcineurin Inhibitor TherapyCalcineurin InhibitorsDrug-induced Skin ReactionsImmunosuppressionImmunosuppression In Kidney TransplantationInflammatory Skin DisordersCutaneous Drug EruptionsDermatologic DisordersDrug-induced Acneiform EruptionDrug-induced Skin EruptionsImmunosuppressive CompoundsNephrotoxic MedicationsTacrolimus TherapyTransplant-associated Skin Reactions
Sirolimus is a new immunosuppressive agent used to prevent rejection in renal allograft recipients in order to reduce the need of potentially nephrotoxic calcineurin inhibitors (cyclosporine, tacrolimus). The cutaneous side effects of sirolimus are not well known and they may have been underestimated. We report 2 cases of follicular acneiform eruptions induced by sirolimus in renal allograft recipients. This dermatologic complication was severe and difficult to treat, and resolved only after discontinuation of sirolimus.
7
Éric Raymond, Jérôme Alexandre, Sandrine Faivre et al. · Journal of Clinical Oncology · 2004 · 500 citations · Full text
Sakari Reitamo, Phyllis I. Spuls, B. Sassolas et al. · British Journal of Dermatology · 2001 · 142 citations
Involvement of the Akt/mTOR pathway on EGF‐induced cell transformation
Masaaki Nomura, Zhiwei He, Ichiko Koyama et al. · Molecular Carcinogenesis · 2003 · 44 citations · Full text